Report of Foreign Issuer (6-k)
June 15 2020 - 6:58AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: June 2020
Commission file number: 001-36578
ENLIVEX THERAPEUTICS LTD.
(Translation of registrant’s name into English)
14 Einstein Street, Nes Ziona, Israel 7403618
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form
40-F ☐
Indicate by check mark
if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark
if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
Remote Access to Annual and
Extraordinary General Meeting of Shareholders
On June
15, 2020, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the
“Company”), informed its shareholders that due to continued
application of regulations restricting gatherings due to COVID 19, the 2020
Annual and Extraordinary General Meeting of Shareholders of the Company (the “Annual Meeting”) on
Wednesday, June 24, 2020, beginning at 4:00 p.m., Israel time, will be held remotely via Zoom. Shareholders wishing to
attend the Annual Meeting will be able to participate by clicking on the link below immediately prior to or during the Annual
Meeting:
https://us02web.zoom.us/j/84302881164
Or access via telephone:
US: +1 929 436 2866 or +1 669
900 6833
South Korea: +82 (0) 2 6022 2322
Hong Kong: +852 5808 6088
Israel: +972 (0) 3 978 6688
United Kingdom: +44 (0) 20 3051
2874
Meeting
ID: 843 0288 1164
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Enlivex Therapeutics Ltd.
|
|
(Registrant)
|
|
|
|
By:
|
/s/ Oren Hershkovitz
|
|
Name:
Title:
|
Oren Hershkovitz
Chief Executive Officer
|
Date: June 15, 2020
2
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Sep 2023 to Sep 2024